Ability Biologics’ Post

🚀 Strategic Partnership Announcement: Anivance AI x Molecular Devices This partnership combines Anivance AI and Molecular Devices’ expertise in 3D cell culture, high-throughput screening, and advanced organ-on-chip platforms to transform the drug development landscape. By accurately simulating human physiological responses, we aim to enhance the precision and efficiency of drug screening and data analysis, accelerating groundbreaking progress in drug discovery and development. “Anivance AI is committed to the global 3R initiative and Taiwan’s ‘Chip Creation Initiative.’ Through our R&D Support Program, we offer a standardized, end-to-end solution covering experimental design and testing, enabling researchers to focus on achieving innovative breakthroughs.”— Prof. Guan Yu Chen Guan-Yu Chen, Founder of Anivance AI Together, Anivance AI and Molecular Devices are driving the application of organ-on-chip technology in the biopharmaceutical sector, accelerating the drug development process. Read more: https://lnkd.in/e7w2Wth3 #AnivanceAI #MolecularDevices #OrganOnChip #DrugDevelopment #Biotechnology #StrategicPartnership

Unlock the potential of your biologics pipeline! Watch our On-Demand webinar, “Maximizing Bioproduction with CELLiST: Leveraging Multiomics and AI for Superior Cell Culture Media,” to discover how advanced techniques can enhance protein yield and optimize production processes. 🚀 Don't miss out on this chance to gain valuable insights. Watch now! https://lnkd.in/g3MJFgAW

🌟 Excited to announce my new blog, AI-Powered Drug Design: Shaping the Future of Therapeutics! In this blog, I share my insights on the crucial understandings we achieve during drug design with AI. From molecular design and optimization to predicting interactions and running simulations, AI is revolutionizing every step of the drug discovery process. 🔍 Dive into the details and discover how AI is paving the way for the next generation of therapeutics.  I would love to hear your thoughts and engage in discussions about the future of drug design! #drugdiscovery #artificialintelligence #bioinformatics #proteinengineering #biotechnology #computationalbiology

Preliminary agendas now available: Bioprocessing Summit Europe brings together 750+ upstream, downstream, bioproduction, and analytical professionals from industry and academia to advance the manufacture, quality, and control of next generation biologics and genetic therapies. This 3-day, 14-track meeting has quickly become a premier event in the European bioprocessing calendar and focuses on the latest innovations in bioprocess R&D as well as the practical solutions to enhance efficiency, speed and cost in biomanufacturing. New for 2025, we are excited to add a new conference stream on #processmodelling and #digitalization, alongside expanded content on #ML/AI, #advanced process control, #developability, #cell culture, #downstream processing, #analytics, and the latest in #celltherapy, #genetherapy, and #RNA therapies. https://lnkd.in/gPypE9E #CHIBioprocessingSummit

Debra Touw, Principal Scientist, Multi-Specifics at AbbVie presented how 12+ years of using Genedata has enabled them to optimize their biologics discovery and engineering workflows as they expanded to new molecule formats, therapeutic modalities, and R&D focus areas. Genedata integrates information from hybridoma, yeast and phage display, single B-cell, computational engineering, and external partners to create building blocks for new therapeutic candidates and lays the groundwork for AI/ML initiatives. With all data in one location, AbbVie can easily compile patent filings, explore legacy information, and manage data and processes across multiple sites.      During the lively Q&A session, Debra addressed the question of onboarding by saying that people use Genedata Biologics because it makes life easier for them, for example, mass spec analysis is easier. #DigitalizingBiopharma #OpenForum

More news in AI-designed binder land: A glimpse into Exscientia's (assuming before acquisition) antibody design efforts. A combo of different models for different tasks. ESM-1 for nominating new improvements, AbMPNN for inverse folding to avoid viral escape. Physics-based modeling and experiments too. It will be interesting to see if/when Recursion ventures into biologics. Preprint: https://lnkd.in/g9vRuKXe

#Supercomputing with Frontier changed our company overnight. BPGbio's CEO Niven R Narain, Ph.D. was recently interviewed by Brian K. Buntz, pharma and biotech editor at Drug Discovery & Development on our partnership with the Oak Ridge National Laboratory and using Frontier, the world’s first exascale supercomputer with its dizzying 1.1 exaflop speed. With power exceeding a quintillion calculations per second – that’s a one followed by 18 zeros – Frontier can accomplish in a heartbeat what would take the entire global population four years of non-stop work. Dive into the latest frontier of drug discovery with Niven R Narain, Ph.D. as he discusses combining our AI-driven approach with the transformative power of Oak Ridge National Laboratory's Frontier supercomputer to reshape biopharmaceutical innovation. https://lnkd.in/gCu_ZpQ2 #DrugDiscovery #AIinHealthcare #BPGbio #FrontierSupercomputer #ai #aidrugdiscovery

Great article in Drug Target Review featuring our CEO, Yanay Ofran. He discusses how we are redefining antibody therapies by creating programmable molecules that can adjust their activity based on their biological environment, with the goal of creating safer and more effective new medicines: https://bit.ly/3ZS0nCt

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/g8XPQSsa #biotech #businessdevelopment #artificialintelligence

Drug discovery is a slow and expensive process. AI is revolutionizing this field by helping identify promising drug targets and design effective drugs through big data analysis and virtual screening. AI can also predict clinical trial outcomes, optimizing the process and accelerating access to potentially life-saving treatments. This technology has the potential to unlock new avenues for drug development and usher in an era of personalized medicine, where treatments are tailored to individual patients. While the pharmaceutical industry is embracing AI, challenges like adapting workflows and addressing ethical considerations remain. The future of drug discovery is bright with AI, promising faster innovation and delivering treatments to patients in greater need. More information on this, in my article published on medium.com. The link to the same is provided below-